PMID- 36723377
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230227
IS  - 2040-3372 (Electronic)
IS  - 2040-3364 (Linking)
VI  - 15
IP  - 8
DP  - 2023 Feb 23
TI  - Microfluidic fabrication of photo-responsive Ansamitocin P-3 loaded liposomes for 
      the treatment of breast cancer.
PG  - 3780-3795
LID - 10.1039/d2nr06215a [doi]
AB  - Ansamitocin P-3 (AP-3) is a promising anticancer agent. However, its low 
      solubility has limited its biomedical applications. The preparation of liposomal 
      formulations for the delivery of low solubility drugs using the microfluidic 
      platform has attracted increasing attention in the pharmaceutical industry. In 
      addition, photodynamic therapy (PDT) is a non-invasive and efficient strategy for 
      the treatment of cancers, making photodynamic liposomes one of the most promising 
      drug delivery systems (DDSs). In this study, a recently developed microfluidic 
      device (swirl mixer) was used for the manufacturing of temperature-sensitive 
      liposomes (TSL) that can be activated by near-infrared stimulation for the 
      treatment of breast cancer. Changing the processing parameters of the 
      microfluidic system allowed for optimizing the properties of the produced 
      liposomes (e.g., particle size and size distribution). For the first time, the 
      anticancer drug AP-3 and the photosensitizer indocyanine green (ICG) were 
      encapsulated into TSL (AP-3/ICG@TSL) during microfluidic processing. The results 
      show that AP-3/ICG@TSL are biocompatible and can significantly reduce the 
      toxicity of AP-3 to normal tissues. After infrared laser irradiation, the heat 
      generated from ICG not only resulted in the cancer cell toxicity, but also 
      facilitated the release of AP-3 in tumor cells. AP-3/ICG@TSL with infrared laser 
      irradiation was found to be able to significantly inhibit the growth of MCF-7 
      multicellular tumor spheroids (MCTSs) in vitro and MCF-7 tumors subcutaneously 
      inoculated in nude mice as an in vivo model. In addition, it also showed no signs 
      of damage to other organs. The current results demonstrated that the AP-3/ICG@TSL 
      fabricated using the microfluidic swirl mixer is a promising DDS for breast 
      cancer therapy.
FAU - Jin, Yi
AU  - Jin Y
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China. 
      xiubo.zhao@cczu.edu.cn.
AD  - Department of Pharmacy, Wujin Hospital Affiliated with Jiangsu University, 
      Changzhou 213000, China.
FAU - Tomeh, Mhd Anas
AU  - Tomeh MA
AD  - Department of Chemical and Biological Engineering, University of Sheffield, 
      Sheffield S1 3JD, UK.
FAU - Zhang, Peng
AU  - Zhang P
AD  - School of Materials Science and Engineering, Changzhou University, Changzhou 
      213164, China.
FAU - Su, Mingzhu
AU  - Su M
AD  - Department of Pharmacy, Wujin Hospital Affiliated with Jiangsu University, 
      Changzhou 213000, China.
FAU - Zhao, Xiubo
AU  - Zhao X
AUID- ORCID: 0000-0002-4620-2893
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China. 
      xiubo.zhao@cczu.edu.cn.
AD  - Department of Chemical and Biological Engineering, University of Sheffield, 
      Sheffield S1 3JD, UK.
FAU - Cai, Zhiqiang
AU  - Cai Z
AUID- ORCID: 0000-0002-9180-675X
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China. 
      xiubo.zhao@cczu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230223
PL  - England
TA  - Nanoscale
JT  - Nanoscale
JID - 101525249
RN  - 0 (Liposomes)
RN  - 69279-90-9 (ansamitocins)
RN  - 80168379AG (Doxorubicin)
RN  - 0 (Antineoplastic Agents)
RN  - IX6J1063HV (Indocyanine Green)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Liposomes/therapeutic use
MH  - Mice, Nude
MH  - Microfluidics
MH  - Doxorubicin
MH  - *Photochemotherapy/methods
MH  - *Antineoplastic Agents/therapeutic use
MH  - *Neoplasms/drug therapy
MH  - Indocyanine Green
MH  - Infrared Rays
MH  - Cell Line, Tumor
EDAT- 2023/02/02 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/02/01 09:43
PHST- 2023/02/02 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/02/01 09:43 [entrez]
AID - 10.1039/d2nr06215a [doi]
PST - epublish
SO  - Nanoscale. 2023 Feb 23;15(8):3780-3795. doi: 10.1039/d2nr06215a.